Balchem (BCPC) Q2 2026 earnings summary

Executive summary

• Achieved record quarterly consolidated sales of $284 million, up 11.2% year-over-year, with all three business segments—Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products—delivering strong sales and profit growth, driven by strategic initiatives and market penetration.

• Net earnings for Q2 2026 rose 16.6% to $44.6 million, with adjusted EBITDA up 12.6% to $77.9 million and adjusted net earnings at $48.1 million.

• Free cash flow for the quarter was $36.2 million, with cash flows from operations at $46.7 million and a cash balance of $63.2 million.

• Strengthened balance sheet through refinancing and amending the revolving credit facility, increasing borrowing capacity to $650 million and extending maturity to 2031.

• Repurchased $29 million of common stock in Q2 and $114 million over the trailing twelve months, reflecting a balanced capital allocation strategy.

Financial highlights

• Consolidated revenue reached a record $284 million, up 11.2% year-over-year, with gross margin at $103.7 million (36.5% of sales), and GAAP earnings per share of $1.39, up from $1.17.

• Adjusted EBITDA was $77.9 million, up 12.6%, with an adjusted EBITDA margin of 27.4%.

• Adjusted net earnings were $48.1 million, up from $41.6 million in the prior year quarter; adjusted EPS was $1.49, up from $1.27.

• Cash flows from operations were $47 million; free cash flow was $36 million; cash on balance sheet was $63 million.

• Operating expenses increased by $2.8 million, mainly due to higher compensation-related costs.

Outlook and guidance

• Management expects continued sales growth, supported by product innovation, operational efficiencies, and strategic growth initiatives.

• Effective tax rate expected to remain in the 22.5%-23% range for the remainder of 2026.

• Marketing investments and omnichannel strategies are expected to further accelerate brand awareness and demand generation.

• No material impact anticipated from recent tariff changes or geopolitical tensions, but ongoing monitoring continues.